Noxafil® PowderMix, Noxafil® (posaconazole) – New formulation approval, expanded indication
May 31, 2021 - The FDA approved Merck’s Noxafil PowderMix delayed-release oral suspension, for the prophylaxis of invasive Aspergillus and Candida infections in pediatric patients 2 years of age and older (who weigh 40 kg or less) who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD) or those with hematologic malignancies with prolonged neutropenia from chemotherapy.
Top